Investors' expectations of strong future growth justify Korn Ferry's high P/E ratio. The potential for a deterioration in earnings is not seen as significant enough to warrant a lower P/E ratio.
$Market Beating Value ETF(PFL1021127)$ My paperfolio’s link can be seen above. The stocks I pick are based on value investing philosophy. I won’t go into what that means in this post. I’m a lot more conservative than your average investor. As such, this portfolio only used 50-60% of its cash to buy stocks, while the rest sat idle. In other words, I am up 13% at the time of writing mostly using only 50-75% of my portfolio’s cash (with some exceptions). As I have seen bu...
光辉国际咨询顾问股票讨论区
My stock performance so far
My paperfolio’s link can be seen above. The stocks I pick are based on value investing philosophy. I won’t go into what that means in this post. I’m a lot more conservative than your average investor. As such, this portfolio only used 50-60% of its cash to buy stocks, while the rest sat idle. In other words, I am up 13% at the time of writing mostly using only 50-75% of my portfolio’s cash (with some exceptions). As I have seen bu...
5年来毛利率基本在94%左右,重点观察费用变化。净资产收益率从11.5%下滑至8.5%左右,直至2022年暴涨至22%。
5年来前四年营收变化不大,2022年暴涨45.3%,营业利润2022年暴涨152%,净利润暴涨186%。2023Q1营收、营业利润和净利润分别增长19.6%,10.2%和2.8%,盈利增速明显放缓,这也是意料中的。
利润表显示近几年利息费用整体增长趋势,2021年利息费用占营业利润的5.4%,负担不算重。其他费用项里面重组和并购没几年都会有笔大的费用,对净利润影响很大。
资产负债率5年来从47%上升到55.3%,2023Q1又下降到51%。
资产负债表显示近期应收增加很快,不过比例还算合理。
商誉达到7.24亿,占净资产15.71亿的46%。长期借款4亿,目前看负担不算重,不过现金就有7亿,似乎保持这么多的长期贷款不是很合理。
5年来现金流经营...
专栏Today's pre-market stock movers: BBIO, LZB, ORA, DOW and more
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $辉瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
暂无评论